GLOBAL HEALTH | GLOBAL PARTNERSHIPS | GLOBAL IMPACT

Dr. Hertzel C. Gerstein MD, MSc, FRCPC

Photo of Hertzel C. Gerstein
Hertzel C. Gerstein Dr.
Deputy Director

Current Positions

  • Deputy Director – Population Health Research Institute
  • Professor – Department of Medicine, Department of Clinical Epidemiology and Biostatistics
  • Associate Member – Department of Clinical Epidemiology & Biostatistics
  • Director – Division of Endocrinology & Metabolism
  • Population Health Institute Chair in Diabetes Research
  • Head – Service of Endocrinology and Metabolism
  • Director – Diabetes Care and Research Program, Hamilton Health Sciences

Bio

Dr. Gerstein is an Endocrinologist and Professor at McMaster University and Hamilton Health Sciences, where he holds the Population Health Institute Chair in Diabetes Research. He is also Director of the Division of Endocrinology & Metabolism and Director of the Diabetes Care and Research Program. Dr. Gerstein has pioneered the application of large simple outcome trials to people with diabetes globally, and developed the concept of dysglycemia as an important risk factor for many of the serious health outcomes that afflict people with an elevated glucose level regardless of diabetes status. He currently leads clinical trials and epidemiologic studies related to: a) the prevention and therapy of diabetes and its many consequences, and b) the role of dysglycemia and relative insulin insufficiency on the development of diabetes, cardiovascular disease, cognitive impairment and other chronic conditions. His research spans over 50 countries, and has been funded by the Canadian Institutes of Health Research, the National Institutes of Health, the Heart and Stroke Foundation, the Canadian Diabetes Association and Industry. Key studies in which he has played or continues to play a major leadership role include HOPE, MICRO HOPE, ACCORD, DREAM, EpiDREAM, ORIGIN, TIDE, ACE, ELIXA and REWIND. Dr. Gerstein has published more than 300 papers, editorials and commentaries, mainly on diabetes-related issues and co-edited the textbook Evidence-Based Diabetes Care. He is an Associate Editor for ACP Journal Club, and is on the editorial board of the Journal of Diabetes and Lancet Diabetes and Endocrinology. He has received several honors including the Canadian Diabetes Association’s Young Scientist Award (1999), Frederick G. Banting award (1999), Charles H. Best award (2007) and Lifetime Achievement Award (2012).

Research Interests

  • Dr. Gerstein has led the application of large simple outcome trials to people with diabetes globally, and developed the concept of dysglycemia as an important risk factor for many of the serious health outcomes that afflict people with an elevated glucose level regardless of diabetes status. He currently leads clinical trials and epidemiologic studies related to: a) the prevention and therapy of diabetes and its many consequences, and b) the role of dysglycemia and relative insulin insufficiency on the development of diabetes, cardiovascular disease, cognitive impairment and other chronic conditions. His research spans over 50 countries, and has been funded by the Canadian Institutes of Health Research, the National Institutes of Health, the Heart and Stroke Foundation, the Canadian Diabetes Association and Industry. Key studies in which he has played or continues to play a major leadership role include HOPE, MICRO HOPE, ACCORD, DREAM, EpiDREAM, ORIGIN, TIDE, ACE, CANVAS, ELIXA and REWIND. In addition to his research, he was the founding director of Diabetes Hamilton — a novel publicly available program that facilitated the ability of people with diabetes to best manage their disease.
  • ORIGINALE
  • ORIGIN Biomarker
  • ORIGIN Genetics
  • ACCORDION
  • REWIND
  • REMIT

Publications are listed in chronological order by descending date. Link takes user to pubMed for publication details.